Papaverine HydrochlorideCAS# 61-25-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 61-25-6 | SDF | Download SDF |
| PubChem ID | 6084 | Appearance | White powder |
| Formula | C20H22ClNO4 | M.Wt | 375.8 |
| Type of Compound | Nitrogen-containing Compounds | Storage | Desiccate at -20°C |
| Solubility | Sparingly soluble in water; slightly soluble in ethan | ||
| Chemical Name | 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline;hydrochloride | ||
| SMILES | COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC.Cl | ||
| Standard InChIKey | UOTMYNBWXDUBNX-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C20H21NO4.ClH/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16;/h5-8,10-12H,9H2,1-4H3;1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Papaverine Hydrochloride Dilution Calculator
Papaverine Hydrochloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.661 mL | 13.3049 mL | 26.6099 mL | 53.2198 mL | 66.5247 mL |
| 5 mM | 0.5322 mL | 2.661 mL | 5.322 mL | 10.644 mL | 13.3049 mL |
| 10 mM | 0.2661 mL | 1.3305 mL | 2.661 mL | 5.322 mL | 6.6525 mL |
| 50 mM | 0.0532 mL | 0.2661 mL | 0.5322 mL | 1.0644 mL | 1.3305 mL |
| 100 mM | 0.0266 mL | 0.133 mL | 0.2661 mL | 0.5322 mL | 0.6652 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Adenosine 5'-monophosphate
Catalog No.:BCC8809
CAS No.:61-19-8
- Dibucaine (Cinchocaine) HCl
Catalog No.:BCC3760
CAS No.:61-12-1
- 2-Methoxycinnamic acid
Catalog No.:BCN5038
CAS No.:6099-03-2
- Geraniin
Catalog No.:BCN2402
CAS No.:60976-49-0
- Bz-Glu-OH
Catalog No.:BCC2922
CAS No.:6094-36-6
- YZ9
Catalog No.:BCC8001
CAS No.:6093-71-6
- 6-Hydroxycoumarin
Catalog No.:BCC9207
CAS No.:6093-68-1
- H-DL-Pro-OH
Catalog No.:BCC3026
CAS No.:609-36-9
- PIR 3.5
Catalog No.:BCC6128
CAS No.:6088-51-3
- Ligularidine
Catalog No.:BCN2141
CAS No.:60872-63-1
- Crotaverrine
Catalog No.:BCN2142
CAS No.:60827-69-2
- Esculentoside B
Catalog No.:BCN5011
CAS No.:60820-94-2
- Mefenamic Acid
Catalog No.:BCC4433
CAS No.:61-68-7
- Phenylephrine HCl
Catalog No.:BCC4335
CAS No.:61-76-7
- 4-Aminohippuric Acid
Catalog No.:BCC4753
CAS No.:61-78-9
- Zoxazolamine
Catalog No.:BCC4751
CAS No.:61-80-3
- H-Leu-OH
Catalog No.:BCC2968
CAS No.:61-90-5
- Tenuazonic acid
Catalog No.:BCN1859
CAS No.:610-88-8
- Isoacetovanillone
Catalog No.:BCN7166
CAS No.:6100-74-9
- Succinylcholine Chloride Dihydrate
Catalog No.:BCC4564
CAS No.:6101-15-1
- Ferulamide
Catalog No.:BCN4129
CAS No.:61012-31-5
- c-JUN peptide
Catalog No.:BCC8085
CAS No.:610273-01-3
- Teicoplanin
Catalog No.:BCC4731
CAS No.:61036-62-2
- N-Desmethylclozapine
Catalog No.:BCC6887
CAS No.:6104-71-8
Oral administration of a lecithin-based delivery form of boswellic acids (Casperome(R)) for the prevention of symptoms of irritable bowel syndrome: a randomized clinical study.[Pubmed:30676012]
Minerva Gastroenterol Dietol. 2019 Mar;65(1):30-35.
BACKGROUND: The purpose of this study was to evaluate the long-term efficacy and the safety of a lecithin-based delivery form of boswellic acids from Boswellia serrata (Casperome(R)) for the prevention of symptoms in otherwise healthy subjects with mild irritable bowel syndrome (IBS). METHODS: The study included 69 otherwise healthy participants with a mild form of IBS who completed a 6-month follow-up period. In total, 34 subjects were assigned to the standard management (SM) group: diet and, if needed, hyoscine butylbromide (Buscopan(R)) or Papaverine Hydrochloride + 10 mg of Atropa belladonna extract; 35 subjects were assigned to supplementation with the Boswellia serrata lecithin-based delivery form (one tablet/day; Casperome(R)). IBS signs and symptoms were evaluated at inclusion (T0), after 3 (T1) and 6 months (T2). The numbers of patients who needed rescue medication were recorded. Adverse events were also evaluated. RESULTS: At baseline, the groups were comparable in terms of demographic and clinical characteristics. At follow-up, compared with the SM group, the Boswellia group showed lower mean score values for almost all self-assed IBS symptoms. A significantly lower need for rescue medications and consultations or medical evaluation/admissions was found in the Boswellia group compared with the SM group. The incidence of minimal adverse events - mainly stipsis - was significantly higher in the SM group. Oxidative stress at T2 was significantly decreased in Boswellia-supplemented subjects. CONCLUSIONS: Boswellia serrata lecithin-based delivery form (Casperome(R)) appears to be effective and safe in improving signs and symptoms in IBS subjects who are otherwise healthy, particularly in comparison with symptomatic drug treatment that may cause side effects and stiptis.
